Top

Published in:

01-08-2009 | Preclinical Study

Glucocorticoid receptor expression in breast cancer associates with older patient age

Authors: Larissa Belova, Bertha Delgado, Masha Kocherginsky, Amal Melhem, Olufunmilayo I. Olopade, Suzanne D. Conzen

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

Breast cancer can be classified according to estrogen (ER), progesterone (PR), and HER2 receptor expression. Recent evidence suggests that activation of the glucocorticoid receptor (GR) contributes to breast cell survival, although the incidence of GR expression in primary human breast tumors is not well established. We therefore evaluated ER, PR, HER2, and GR by immunohistochemistry from 231 patients and found that while African American (AA) patient tumors were much more likely to be ER negative compared to tumors from non-AA patients, GR expression was significantly higher in tumors from patients ≥50 regardless of ancestry. Prospective examination of GR expression in tumors should be considered to determine whether GR contributes to long-term clinical outcome.

Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH et al (2006) Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 209(3):317–327. doi:10.1002/path.1982 PubMedCrossRef

Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI (2008) Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol 23(1):77–85PubMed

Amsterdam A, Tajima K, Sasson R (2002) Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol 64(5–6):843–850. doi:10.1016/S0006-2952(02)01147-4 PubMedCrossRef

Casey TM, Plaut K (2007) The role of glucocorticoids in secretory activation and milk secretion, a historical perspective. J Mammary Gland Biol Neoplasia 12(4):293–304. doi:10.1007/s10911-007-9055-3 PubMedCrossRef

Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD (2006) Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5(8):933–940PubMedCrossRef

Runnebaum IB, Bruning A (2005) Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin Cancer Res 11(17):6325–6332. doi:10.1158/1078-0432.CCR-05-0182 PubMedCrossRef

Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64(5):1757–1764. doi:10.1158/0008-5472.CAN-03-2546 PubMedCrossRef

Bamberger CM, Schulte HM, Chrousos GP (1996) Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17(3):245–261. doi:10.1210/er.17.3.245 PubMed

Brewer JA, Vogt SK, Sleckman BP, Swat W, Kanagawa O, Muglia LJ (2002) Knock-ins and conditional knockouts: in vivo analysis of glucocorticoid receptor regulation and function. Endocr Res 28(4):545–550. doi:10.1081/ERC-120016839 PubMedCrossRef

10.

Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL (2008) Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology 52(3):314–324. doi:10.1111/j.1365-2559.2007.02953.x PubMedCrossRef

11.

Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML et al (2006) Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer 53(3):303–310. doi:10.1016/j.lungcan.2006.05.005 PubMedCrossRef

12.

Rajatapiti P, Kester MH, de Krijger RR, Rottier R, Visser TJ, Tibboel D (2005) Expression of glucocorticoid, retinoid, and thyroid hormone receptors during human lung development. J Clin Endocrinol Metab 90(7):4309–4314. doi:10.1210/jc.2005-0556 PubMedCrossRef

13.

Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276(20):16649–16654. doi:10.1074/jbc.M010842200 PubMedCrossRef

14.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492 PubMedCrossRef

15.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143(1):109–118. doi:10.1016/j.jss.2007.03.085 PubMedCrossRef

16.

Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643. doi :10.1002/(SICI)1097-0215(19970317)70:6<639::AID-IJC2<3.0.CO;2-WPubMedCrossRef

17.

Purmonen S, Manninen T, Pennanen P, Ylikomi T (2008) Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep 19(6):1627–1634PubMed

18.

Lange CA (2008) Challenges to defining a role for progesterone in breast cancer. Steroids 73:914–921. doi:10.1016/j.steroids.2007.12.023 PubMedCrossRef

19.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093 PubMedCrossRef

20.

Hall RE, Lee CS, Alexander IE, Shine J, Clarke CL, Sutherland RL (1990) Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels. Int J Cancer 46(6):1081–1087. doi:10.1002/ijc.2910460622 PubMedCrossRef

21.

Krishnan AV, Swami S, Feldman D (2001) Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 77(1):29–37. doi:10.1016/S0960-0760(01)00030-9 PubMedCrossRef

22.

Kinyamu HK, Archer TK (2003) Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 23(16):5867–5881. doi:10.1128/MCB.23.16.5867-5881.2003 PubMedCrossRef

23.

Clarke M (2006) Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview. Ann Oncol 17(Suppl 10):x59–x62. doi:10.1093/annonc/mdl238 PubMedCrossRef

24.

Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1899–1905. doi:10.1158/1055-9965.EPI-06-0191 PubMedCrossRef

25.

Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL (2008) Early onset of breast cancer in a group of British black women. Br J Cancer 98(2):277–281. doi:10.1038/sj.bjc.6604174 PubMedCrossRef

26.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW et al (2008) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat; Epub ahead of print

27.

Newman LA, Martin IK (2007) Disparities in breast cancer. Curr Probl Cancer 31(3):134–156. doi:10.1016/j.currproblcancer.2007.01.003 PubMedCrossRef

28.

Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed

29.

Lowenberg M, Stahn C, Hommes DW, Buttergereit F (2008) Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 73(9–10):1025–1029. doi:10.1016/j.steroids.2007.12.002 PubMedCrossRef

Title: Glucocorticoid receptor expression in breast cancer associates with older patient age
Authors: Larissa Belova
Bertha Delgado
Masha Kocherginsky
Amal Melhem
Olufunmilayo I. Olopade
Suzanne D. Conzen
Publication date: 01-08-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0136-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer

Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes

Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation

Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer